HNSBF News and Press, Hansa Biopharma AB From 12/14/23

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...

2023-10-26 19:30:24 ET Hansa Biopharma AB (publ) (HNSBF) Q3 2023 Results Conference Call October 26, 2023 08:00 AM ET Company Participants Søren Tulstrup - Chief Executive Officer Matt Shaulis - Chief Commercial Officer and U.S. President Donato Spota - Chie...

2023-10-26 12:42:13 ET More on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial information for Hansa Biopharma For further details see: Hansa Biopharma reports Q3 results

2023-07-20 13:58:09 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2023 Earnings Call Transcript July 20, 2023 08:00 AM ET Company Participants Soren Tulstrup - President and CEO Matthew Shaulis - CCO Donato Spota - SVP and CFO Conference Call Participants G...

2023-07-20 09:34:17 ET Hansa Biopharma press release ( OTCPK:HNSBF ): Q2 GAAP EPS of -SEK4.79. Revenue of SEK36.7M (+24.0% Y/Y). For further details see: Hansa Biopharma GAAP EPS of -SEK4.79, revenue of SEK36.7M

2023-04-20 14:50:06 ET Hansa Biopharma AB (publ) (HNSBF) Q1 2023 Earnings Conference Call April 20, 2023 08:00 ET Company Participants Søren Tulstrup - President & Chief Executive Officer Donato Spota - Senior Vice President & Chief Financial Officer ...

2023-04-20 03:47:06 ET Hansa Biopharma press release ( OTCPK:HNSBF ): Q1 GAAP EPS of -SEK 3.92. Revenue of SEK 24.2M (-20.1% Y/Y). For further details see: Hansa Biopharma GAAP EPS of -SEK 3.92, revenue of SEK 24.2M

2023-04-20 03:42:05 ET Hansa Biopharma ( OTCPK:HNSBF ) expects t otal Q1 revenue of SEK24.2M including SEK14.3M in product sales and SEK9.9M in revenue recognition mainly under the agreement with Sarepta. Appointed Matthew Shaulis as Chief Commercial Officer ...

Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...

Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Conference Call February 02, 2023, 08:00 AM ET Company Participants Søren Tulstrup - President and CEO Donato Spota - SVP and CFO Conference Call Participants Gonzalo Attali - ABG Sundal Collier Zoe Ka...